Articles related to DRUG EFFICACY

Tranexamic acid was associated with lower rates of major bleeding among patients undergoing urologic surgery in a prespecified POISE-3 trial analysis, while thrombotic event rates remained similar between treatment groups.

Researchers identified a metabolic pathway in which amino acid breakdown generates propionyl-CoA, sustaining cholesterol production and androgen signaling in prostate cancer models. The findings suggest a potential mechanism of hormone therapy resistance, though clinical relevance remains unproven.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

Two phase 3 trials found upadacitinib increased scalp, eyebrow, and eyelash regrowth in adolescents and adults with severe alopecia areata. Longer-term safety, durability, and regulatory review remain important considerations.

Daily low-dose endoxifen reduced mammographic breast density versus placebo in premenopausal women, with fewer tolerability concerns at 1 mg. Whether this surrogate response translates into lower breast cancer incidence remains unknown.

In a phase 3 trial of 214 adults with generalized anxiety disorder, a single dose of DT120 orally disintegrating tablets produced greater reductions in anxiety scores than placebo through 12 weeks. Full peer-reviewed data and longer-term results remain pending.